Bispecific antibodies represent a rapidly growing therapeutic ... CEO of Light Chain Bioscience. “The native structure of κλ bodies is likely to represent a significant advantage.” ...

Bispecific antibodies combine two therapeutic antibodies into one, simultaneously utilizing the effect of both to benefit patients. However, currently available technologies to produce these two ...

Bispecific antibodies (bsAbs) utilize the properties of two antibodies and integrate them for parallel recognition of various antigens or epitopes. Such a “two-target” functionality implies ...

A bispecific antibody (BsAb) is a type of artificial protein with the ability to bind to two distinct antigens or two epitopes of one antigen at the same time. Bispecific antibodies can assume a ...

A custom antibody manufacturer is testing the best combination of molecular parts for bispecific manufacturing. According to Stefan Schmidt, PhD, CEO of Evitria, the company offers to test in ...

However, the new antibody design addresses these challenges. Its modular structure includes a bispecific antibody produced in bulk and a synthetic peptide tailored to individual tumors.

New data suggests researchers may have found one of their most promising candidates yet for the next generation in immunotherapy drugs — bispecific antibodies targeting two key proteins in ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is ...

This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to ...